Allena Pharmaceuticals Announces Initial Data from Phase 1 Trial of ALLN-346
November 30, 2020 08:00 ET
|
Allena Pharmaceuticals, Inc.
-- Single-Ascending Doses of ALLN-346 Oral Enzyme Well-Tolerated ---- Non-Absorption of ALLN-346 Demonstrated ---- Advancing to Phase 1b Multiple-Ascending Dose Study and Phase 2 Proof-of-Concept...
Allena Pharmaceuticals to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference
November 24, 2020 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
November 09, 2020 08:00 ET
|
Allena Pharmaceuticals, Inc.
-- Presented Data at 53rd Annual Meeting of the American Society of Nephrology (ASN) Highlighting Consistent Treatment Effects Across Phase 2 and 3 Clinical Trials of Reloxaliase in Enteric...
Allena Pharmaceuticals to Participate Virtually in Upcoming Investor Conferences in November
November 03, 2020 08:01 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Appoints Ann Miller, M.D. to its Board of Directors
October 05, 2020 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Announces $25 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures
September 30, 2020 08:00 ET
|
Allena Pharmaceuticals, Inc.
-- Extends Allena’s Cash Runway into 4Q 2021 ---- Debt Can be Converted into Equity at a Price of $4.10 Per Share -- NEWTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc....
Allena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney Disease
September 08, 2020 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals to Present Virtually at Upcoming Investor Conferences in September
September 03, 2020 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,...
Allena Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update
August 05, 2020 08:00 ET
|
Allena Pharmaceuticals, Inc.
-- Expanding URIROX-2 Trial Sites; Interim Analysis on Track for the First Quarter of 2022 –- -- Initiated Phase 1 Clinical Trial of ALLN-346; Initial Data Expected in the Fourth Quarter of...
Allena Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
August 04, 2020 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...